<PAGE>


                                     FORM 10-QSB

                          SECURITIES AND EXCHANGE COMMISSION
                                Washington, D.C. 20549

(Mark One)

/x/                   QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
                        OF THE SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended September 30, 1996

                                          OR

/ /                  TRANSITION REPORT UNDER SECTION 13 OR 15(D)
                        OF THE SECURITIES EXCHANGE ACT OF 1934
              For the transition period from ___________ to ___________

                           Commission file number  0-25242

                             PREMIER LASER SYSTEMS, INC.
                             ----------------------------
                (Exact name of registrant as specified in its charter)

         CALIFORNIA                                    33-0472684
         ----------                                 ---------------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
 incorporation or organization)

                          3 Morgan, Irvine, California 92618
                          ----------------------------------
                       (Address of principal executive offices)

                                    (714) 859-0656
                                    --------------
                             (Issuer's telephone number)

                         -----------------------------------
                 (Former name, former address and former fiscal year,
                            if changed since last report)

    Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
Yes  X   No
    ---     ---

                  APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                     PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

    Check whether the registrant has filed all documents and reports required
to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934
after the distribution of securities under a plan confirmed by a court.
Yes      No
    ---     ---

                        APPLICABLE ONLY TO CORPORATE ISSUERS:

    State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date (November 11, 1996):

              Class A Common Stock:         7,154,054 Shares
              Class E-1 Common Stock:       1,256,818 Shares
              Class E-2 Common Stock:       1,256,818 Shares

    Transitional Small Business Disclosure Format (check one):
Yes      No  X
    ---     ---

<PAGE>

PART I.  FINANCIAL INFORMATION


Item 1.       FINANCIAL STATEMENTS


    The unaudited financial information for the three and six month periods
ended September 30, 1996 and comparative financial information for the prior
year, together with the balance sheets as of September 30, 1996 and March 31,
1996 of Premier Laser Systems, Inc. (the "Company") are attached hereto and
incorporated herein by this reference.

Item 2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

    This Quarterly Report contains forward-looking statements including, 
without limitation, statements concerning future cost of sales and future 
gross margins on sales. The Company's actual results may differ significantly 
from the results discussed in these forward-looking statements. Factors that 
may cause such differences include market acceptance of the Company's 
products, prices charged by the Company's suppliers, future changes in the 
Company's technology and the effects of the introduction of new products by 
the Company's competitors, among others.

RESULTS OF OPERATIONS

    Net sales by the Company for the quarter ended September 30, 1996 (the 
"1996 Quarter") increased approximately 463% to $1,160,000 as compared to 
$206,000 for the quarter ended September 30, 1995 (the "1995 Quarter").  Net 
sales for the 1996 Quarter were significantly higher than expected during the 
summer months, which ordinarily produces a slowing of sales, as a result of 
an increase in sales to the dental industry.  The increased sales to the 
dental industry reflected a change in the mix of product sales, including 
higher sales of the Company's MOD argon laser, which was cleared for teeth 
whitening in the 1996 Quarter, as well as increased sales of its Arago argon 
laser and Aurora diode laser. Net sales for the six month period ended 
September 30, 1996 (the "1996 Period") increased approximately 657% to 
$2,414,000 from $319,000 from the six month period ended September 30, 1995 
(the "1995 Period").  Sales in the 1995 Period of Nd:YAG, Er:YAG and other 
laser products continued to be adversely affected by the lack of working 
capital during the first three quarters of the fiscal year ended March 31, 
1995 ("fiscal 1995") to fund the purchase of inventory components (some of 
which have long supply lead times) and manufacturing operations.

    The Company recorded positive gross profit in the 1996 Quarter and 1996 
Period of $414,000 and $640,000, respectively, as compared to a negative 
gross profit of $301,000 and $639,000 in the 1995 Quarter and the 1995 
Period, respectively.  The increase in gross profit to 36% in the 1996 
Quarter is due primarily to the settlement and termination of the Company's 
joint marketing agreement with International Biolaser Corporation (IBC). This 
agreement had previously required the Company to remit a majority of the 
gross profit for sales of its MODTM argon laser to IBC.  In addition, if 
production volumes increase in future periods, management anticipates higher 
absorption of manufacturing costs and increased utilization of the Company's 
manufacturing personnel, which could lead to increasing positive gross 
margins based upon management's current calculation of the Company's standard 
cost of sales.

    Selling and marketing expenses totaled $490,000 for the 1996 Quarter and
$952,000 for the 1996 Period, as compared to $299,000 for the 1995 Quarter and
$495,000 for the 1995 Period.  The increase was primarily attributable to
marketing and sales efforts related to the Company's dental products.  These
expenses primarily included increased commissions and related selling expenses,
expenses of sales and marketing personnel, trade show attendance and advertising
expenses.  Sales and marketing expenses for the 1996 Period also included
expenses relating to the initial showing of the Company's Er:YAG laser at the
annual meetings of the American Society


                                      -2-
<PAGE>

of Cataract and Refractive Surgeons and the American Academy of Ophthalmology.

    Research and development expenses decreased to $267,000 and $349,000 for
the 1996 Quarter and 1996 Period, as compared to $504,000 and $760,000 for the
1995 Quarter and 1995 Period respectively.  These amounts reflected
reimbursements from the Small Business Innovative Research grant awarded to the
Company of $457,000 in the 1996 Period and $20,000 in the 1995 Period.

    Settlement of joint marketing agreement expenses in the 1996 Quarter 
included a one time writedown associated with the settlement and termination 
of the Company's marketing agreement with IBC. As part of this settlement, the 
Company guaranteed approximately $201,000 of indebtedness to a third party, 
in exchange for exclusive rights to the MOD argon laser technology.  The 
Company has fully reserved for this guarantee and a note receivable from IBC.

    General and administrative expenses decreased 37% to $281,000 in the 1996
Quarter from $449,000 in the 1995 Quarter.  This decrease was primarily
attributable to reduction of expenses associated with the annual report
preparation.  General and administrative expenses for the 1996 Period decreased
36%, to $608,000 from $950,000 in the 1995 Period.  This reduction was due to
the same factor as prevailed during the 1996 Quarter, as well as the reduction
of accounting, legal and public relations expenses.

    Net interest income decreased to a net interest expense of $63,000 in the
1996 Quarter from net interest income of $26,000 in the 1995 Quarter.  Net
interest income also decreased from a net interest expense of $70,000 in the
1996 Period from net interest income of $120,000 in the 1995 Period.  These
decreases reflected the decreased cash available for the Company to invest and
an increase in borrowings to $1,000,000 under the Company's credit facility with
Silicon Valley Bank (the "Credit Facility").

    The Company's net losses from operations decreased to $973,000 and 
$1,670,000 in the 1996 Quarter and 1996 Period from $1,527,000 and $2,723,000 
in the 1995 Quarter and 1995 Period, respectively.  These decreases were 
primarily attributable to the increase in sales and decreases in general and 
administrative expenses and research and development expenses, offset in part 
by increases in sales and marketing expenses and expenses relating to the 
settlement of the Company's joint marketing agreement with IBC.

LIQUIDITY AND CAPITAL RESOURCES

    The Company's operations have been financed through the proceeds from the
sale of the Company's equity securities, including its Initial Public Offering
("IPO"), revenues from operations, the proceeds from an SBIR grant and funding
from the Credit Facility with Silicon Valley Bank.  The Company's principal
capital requirements include the financing of inventory, accounts receivable,
research and development activities, the development of an ophthalmic and a
surgical sales force, the development of marketing programs and the acquisition
and/or licensing of patents.

    At September 30, 1996, the Company had a cash balance of $121,000 and
working capital of $3,375,000.  This represents an increase from March 31, 1996
of $86,000 in cash and cash equivalents.  This increase in cash and cash
equivalents was largely due to borrowings under the Credit Facility and cash
received from the exercise of Class A Warrants, partially offset by cash used in
operations.


                                      -3-
<PAGE>

    On October 18, 1996, the Company closed a secondary offering of 
securities (the "Offering"). The net proceeds of the offering were 
$10,676,750.

    At September 30, 1996, the Company's indebtedness consisted of a $481,195
note payable to Pfizer HPG (the "Pfizer Note"), $1,000,000 due to Silicon Valley
Bank on the Credit Facility and a remaining guarantee for an IBC third party
payable of $169,000.  The Pfizer Note, which was secured by certain of the
Company's tangible and intangible assets was paid, in November 1996, following
completion of the Offering.

    The Company's Credit Facility with Silicon Valley Bank permits borrowings
of up to $1,000,000 based on the value of the 1,150,000 shares of common stock
of Mattan Corporation (the "Mattan Shares") held by the Company.  Borrowings
under the Credit Facility are secured by the Mattan Shares, bear interest at the
rate of 1.0% per annum over the prime rate of interest, and are due and payable
in April, 1997.  In connection with the Credit Facility, the Company issued to
such lender warrants to purchase up to 9,756 shares of the Company's Class A
Common Stock at an exercise price equal to $10.25 per share.  As of September
30, 1996, the Company had drawn approximately $1,000,000 on this Credit
Facility.

    At March 31, 1996, the Company had net operating loss carryforwards for
federal income tax purposes totaling approximately $16,319,000 which will begin
to expire in fiscal 2007.  Net operating loss carryforwards for state income tax
purposes totaling approximately $7,895,000 at March 31, 1996 begin to expire in
fiscal 1998.  The Tax Reform Act of 1986 includes provisions which may limit the
net operating loss carryforwards available for use in any given year if certain
events occur, including significant changes in stock ownership.  Utilization of
the Company's net operating loss carryforwards to offset future income may be
limited.

    The Company's future capital requirements will depend on many factors,
including the progress of the Company's research and development activities, the
scope and results of preclinical studies and clinical trials, the costs and
timing of regulatory approvals, the rate of technology advances by the Company,
competitive conditions within the medical laser industry, the establishment of
manufacturing capacity and the establishment of collaborative marketing and
other relationships which may either involve cash infusions to the Company, or
require additional cash from the Company.  Management believes that short-term
assets, cash generated through expected future revenues, the Credit Facility and
SBIR grants and the net proceeds of the Offering will be adequate to satisfy its
working capital needs for at least the next 12 months.  After that period the
Company's ability to meet its working capital needs will be dependent on its
ability to achieve a positive cash flow from operations and profitable
operations, in addition to its ability to secure additional debt or equity
financing.  No assurance can be given that the Company will be able to achieve a
positive cash flow from operations, profitable operations or secure financing on
acceptable terms.

SEASONALITY OF BUSINESS

    To date, the Company's revenues have typically been significantly higher in
the second and fourth calendar quarters.  This seasonality reflects the timing
of major medical and dental industry trade shows in these quarters,
significantly reduced sales during the summer and the effect of year end tax
planning influencing the purchasing of capital equipment for depreciation during
the fourth


                                      -4-
<PAGE>

calendar quarter.  Although revenues during the summer of 1996 did not follow 
this historical pattern, the Company expects that this seasonality will 
continue in the future.

GOVERNMENT GRANTS

    The Company has been awarded a SBIR grant for approximately $750,000 for
the study of laser cataract emulsification.  Approximtely $697,634 of this
amount was drawn at September 30, 1996.  The remainder of the grant can be drawn
over the next six months upon the achievement of specified criteria.

POTENTIAL FUTURE CHARGE TO INCOME RESULTING FROM CONVERSION OF ESCROW SHARES

    The Securities and Exchange Commission has adopted a position with 
respect to arrangement such as the one entered into among the Company and the 
holders of its outstanding Class E-1 and Class E-2 Common Stock (the "Escrow 
Shares") which provides that in the event any shares are released from escrow 
to certain persons who are officers, directors, employees or consultants of 
the Company, compensation expense will be recorded for financial reporting 
purposes.  Accordingly, the Company expects, in the event of the release of 
the Escrow Shares from escrow, to recognize substantial noncash charges to 
earnings during the periods in which the criteria for release of the Escrow 
Shares are met, which would have the effect of significantly increasing the 
Company's loss or reducing or eliminating earnings, if any, at such time.  
The recognition of such compensation expense by the Company may have a 
depressive effect on the market price of the Company's securities.

    The Escrow Shares will be automatically converted into Class A Common Stock
(at a conversion rate of one share of Class A Common Stock for each Escrow
Share) in the event that the Company meets certain criteria relating to the
market price of the Class A Common Stock or the achievement by the Company of
certain levels of "income," as defined.  Different criteria relate to the Class
E-1 Common Stock and Class E-2 Common Stock.  For these purposes, "income" means
the Company's net income before provision for income taxes, including earnings
from joint ventures, distribution agreements and licensing agreements, but
exclusive of any other earnings that are classified as an extraordinary item,
and exclusive of charges to income that may result from conversion of the Escrow
Shares into Class A Common Stock, as stated in the Company's financial
statements audited by the Company's independent accountants.

    If none of the pretax net income or market price levels are attained, the
Escrow Shares, as well as any dividends or other distributions made with respect
thereto, will be cancelled.  The pretax net income and market price levels were
determined by negotiation between the Company and the Company's underwriter for
the IPO and should not be construed to imply or predict any future earnings by
the Company or any increase in the market price of its securities.  There can be
no assurance that such earnings and market price levels will be attained or that
any or all of the Escrow  Shares will be converted into Class A Common Stock.


                                      -5-
<PAGE>

PART II.  OTHER INFORMATION

Item 1.  LEGAL PROCEEDINGS.

    In March 1994, the Company instituted litigation in the U.S. District
Court, Central District of California, against Infrared Fiber Systems, Inc., a
Delaware corporation ("IFS") which contracted to supply optical fiber to the
Company for the Company's Er:YAG laser.  Two of IFS' senior officers are also
named as defendants.  The Company's complaint in this matter alleges that IFS
and two if its officers made misrepresentations to the Company and that IFS
breached its agreement to supply fibers and certain warranties concerning the
quality of the fiber to be provided.  The Company is seeking damages and an
injunction requiring IFS to subcontract the production of optical fiber to a
third party, as provided in the supply agreement.  In April 1994, IFS filed a
general denial and a cross-complaint against the Company alleging breach of
contract and intentional interference with prospective economic advantage,
seeking compensatory damages "in excess of $500,000," punitive damages and a
judicial declaration that the contract has been terminated and that IFS is free
to market its fibers to others.  In September 1996, IFS filed a new
cross-complaint alleging the same causes of action and seeking substantially the
same relief in the Orange County California Superior Court.  The Company has
filed an answer to the complaint, denying the allegations and asserting several
affirmative defenses.

    IFS has agreed to license certain fiber technologies, to which the Company
claims exclusive license rights, to Coherent, Inc. ("Coherent"), a competitor of
the Company.  Coherent joined the above federal litigation on behalf of IFS,
seeking a declaration that IFS had the legal right to enter into this license
and supply the fiber covered by that agreement, and then subsequently filed a
new complaint in the Orange County California Court for declaratory relief,
seeking an order that the Company's original agreement with IFS applied only to
a specific type of optical fiber.  The Company has answered this complaint.

    In May 1995, the Company instituted litigation concerning this dispute in
the Orange County California Superior Court against Coherent, Westinghouse
Electric Corporation ("Westinghouse") and an individual employee of Westinghouse
who was an officer of IFS from 1986 to 1993, when the events involved in the
federal action against IFS took place and while Westinghouse owned a substantial
minority interest in IFS.  The complaint charges that Coherent conspired with
IFS in the wrongful conduct which is the subject of the federal lawsuit
described above and interfered with the Company's contracts and relations with
IFS and with prospective contracts and advantageous economic relations with
third parties.  The complaint asserts that Westinghouse is liable for its
employee's wrongful acts as an IFS executive while acting within the scope of
his employment at Westinghouse.  The lawsuit seeks injunctive relief and
compensatory damages.  In October 1995, the federal action was stayed by order
of the court in favor of the California state court action, in which the
pleadings have been amended to include all claims asserted by the Company in the
federal action.


                                         -6-

<PAGE>

    In July 1996, the court in the California state court action granted
demurrers by Westinghouse and the employee of Westinghouse to all causes of
action against them, as well as all but one of the Company's claims against
Coherent.  As a result, the claims that are the subject of the granted demurrers
have been dismissed, subject to the Company's right to appeal.  The Company has
decided that it will file an appeal of these decisions.  No trial date has been
set as to the remaining outstanding causes of action.

    In September 1996, the Company instituted litigation in the Salt Lake City,
Utah State Court against IBC.  The Company's complaint alleged, among other
things, conversion, breach of contract and breach of fiduciary duty by IBC as a
result of actions taken by IBC with respect to the collection of accounts
receivable due to the Company.  The court in this matter subsequently issued a
temporary restraining order against IBC, prohibiting it from, among other
things, taking actions to collect receivables generated by the Company's sale of
its products.  IBC has filed a cross-complaint against the Company, alleging
that the Company breached an agreement between the parties, and seeking 
monetary damages.  Management of the Company believes, based in part on 
discussions with counsel, that IBC's cross-complaint is without merit and
intends to vigorously defend the action.

Item 2.  CHANGES IN SECURITIES.

    Not Applicable.

Item 3.  DEFAULTS UPON SENIOR SECURITIES.

    Not Applicable.

Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

    Not Applicable.

Item 5.  OTHER INFORMATION.


    None.

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K.

    (a)  Exhibits.

    10.1      Letter agreement dated August 14, 1996 between the Registrant and
              LaserMed (incorporated herein by this reference to Exhibit 10.41
              to the Registrant's Registration Statement on Form SB-2, File No.
              333-04219).

    10.2      Agreement dated August 12, 1996 between the Registrant and
              Circuit Tree Medical, Inc. (incorporated herein by this reference
              to Exhibit 10.42 to the Registrant's Registration Statement on
              Form SB-2, File No. 333-04219).


                                         -7-

<PAGE>

    10.3      Letter agreement dated August 24, 1996 between the Registrant,
              Tower Financial Group and International Biolaser Corporation
              (incorporated herein by this reference to Exhibit 10.43 to the
              Registrant's Registration Statement on Form SB-2, File No.
              333-04219).

    10.4      Amendment to Loan Agreement dated October 9, 1996 between the
              Registrant and Silicon Valley Bank (incorporated herein by this
              reference to Exhibit 10.44 to the Registrant's Registration
              Statement on Form SB-2, File No. 333-04219).

    (b)  Reports on Form 8-K.  No reports on Form 8-K were filed during the
quarter for which this report is filed.

    In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                             PREMIER LASER SYSTEMS, INC.



Dated:  November 12, 1996    By:  /S/ COLETTE COZEAN
                                -----------------------------------------------
                               Colette Cozean, Chief Executive Officer, as duly
                               authorized officer on behalf of the registrant


Dated:  November 12, 1996    By:  /S/ MICHAEL HIEBERT
                                -----------------------------------------------
                               Michael Hiebert, Chief Financial Officer
                               (Principal Financial Officer)


                                         -8-


<PAGE>
Attachment to Quarterly Report for the quarter ended September 30, 1996



                              PREMIER LASER SYSTEMS INC.

                  FINANCIAL STATEMENTS (UNAUDITED) FOR THE SIX MONTH

                           PERIOD ENDED SEPTEMBER 30, 1996


                                      -9-

<PAGE>

                             PREMIER LASER SYSTEMS, INC.

                                    BALANCE SHEET
                                     (UNAUDITED)
<TABLE>
<CAPTION>

                                                                    SEPTEMBER 30,   SEPTEMBER 30,     MARCH 31,
                                                                        1996             1996           1996
                                                                  -----------------------------------------------
                                                                                    AS ADJUSTED
<S>                                                               <C>                <C>           <C> 
  Cash and cash equivalents                                            $121,043      $9,699,321       $35,463
  Short-term investments                                              3,037,518       3,037,518     4,547,377
  Accounts receivable, net of allowance for doubtful accounts                                   
    of $154,677 and $176,722                                            933,391         933,391       508,315
  Inventories                                                         2,651,446       2,651,446     2,185,355
  Prepaid expenses and other current assets                             432,285         432,285       419,504
  Deferred offering costs                                               501,528               0              
                                                                  -------------------------------------------
         Total current assets                                         7,677,211      16,753,961     7,696,014
  Property and equipment, net                                           440,388         440,388       493,942
  Intangibles, net                                                    7,095,982       7,095,982     7,353,462
  Other assets                                                            6,150           6,150       131,150
                                                                  -------------------------------------------
                                                                    $15,219,731     $24,296,481   $15,674,568
                                                                  -------------------------------------------
                                                                  -------------------------------------------
                                                                                                
         LIABILITIES AND SHAREHOLDERS' EQUITY                                                   
                                                                                                
Current liabilities:                                                                            
  Accounts payable                                                   $2,042,716        $942,716    $1,208,219
  Accrued liabilities                                                   608,775         590,637       188,108
  Notes payable to related party                                        481,195               0       481,195
  Notes payable other                                                 1,169,332       1,169,332              
                                                                  -------------------------------------------
         Total current liabilities                                    4,302,018       2,702,685     1,877,522
                                                                  -------------------------------------------
                                                                                               
Commitments and contingencies 
                         
Shareholders' equity               
  Preferred stock--8,850,000 shares authorized, no shares issued
     and outstanding        
  Common stock--Class A--no par value, 35,600,000 shares 
     authorized; 4,750,250 shares outstanding at September 30, 
     1996, 7,154,054 shares outstanding at September 30,
     1996, as adjusted                                               16,567,349      26,068,989    16,317,376
  Common stock--Class E-1- no par value, 2,200,000 shares 
     authorized; 1,256,818 shares issued and outstanding at 
     September 30, 1996                                               4,769,878       4,769,878     4,769,878
  Common stock-- Class E-2--no par value, 2,200,000 shares 
     authorized: 1,256,818 shares issued and outstanding at 
     September 30, 1996                                               4,769,878       4,769,878     4,769,878
  Class A warrants                                                    2,295,328       2,295,328     2,321,057
  Class B warrants                                                      453,304       1,627,748       376,774
  Warrants to purchase Class A common stock                             192,130         192,130       192,130
  Unrealized holding gain on short-term investments                   2,156,508       2,156,508     3,666,367
  Accumulated deficit                                               (20,286,662)    (20,286,662)  (18,616,414)
                                                                  -------------------------------------------
         Total shareholders' equity                                  10,917,713      21,593,797    13,797,046
                                                                  -------------------------------------------
                                                                    $15,219,731     $24,296,481   $15,674,568
                                                                  -------------------------------------------
                                                                  -------------------------------------------
</TABLE>


                                      -10-
<PAGE>

                             PREMIER LASER SYSTEMS, INC.

                               STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>

                                                          Three Months Ended            Six Months Ended
                                                             September 30,                September 30,
                                                    ----------------------------------------------------------
                                                         1996           1995           1996           1995
                                                    ----------------------------------------------------------
<S>                                                   <C>           <C>            <C>            <C>
Net Sales                                             $1,160,056       $206,204     $2,414,138       $318,768
Cost of Sales                                            745,675        506,996      1,774,286        957,349
                                                    ----------------------------------------------------------
Gross profit (loss)                                      414,381       (300,792)       639,852       (638,581)

Selling and marketing expenses                           490,102        298,853        951,874        494,684
Research and development expenses                        267,138        503,566        348,917        759,525
Settlement of joint marketing agreement                  286,740                       331,740
General and administrative expenses                      280,832        449,246        607,618        950,324
                                                    ----------------------------------------------------------

     Loss from operations                               (910,431)    (1,552,457)    (1,600,297)    (2,843,114)

Interest (income) expense, net                            62,757        (25,594)        69,951       (120,043)
                                                    ----------------------------------------------------------

     Net Loss                                          ($973,188)   ($1,526,863)   ($1,670,248)   ($2,723,071)
                                                    ----------------------------------------------------------
                                                    ----------------------------------------------------------


Loss per share                                             (0.20)         (0.34)         (0.35)         (0.60)
                                                    ----------------------------------------------------------
                                                    ----------------------------------------------------------

  Weighted average number of shares
  outstanding                                          4,750,250      4,501,899      4,735,704      4,501,899
                                                    ----------------------------------------------------------
                                                    ----------------------------------------------------------
</TABLE>


                                      -11-

<PAGE>

PREMIER LASER SYSTEMS, INC.
Statements of Cash Flows
(Unaudited)

<TABLE>
<CAPTION>
 
                                                               Six Months Ended 
                                                                 September 30,
                                                             1996            1995
                                                          -----------    -----------
<S>                                                     <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss                                                 $ (1,670,248)  $ (2,723,071)
Adjustments to reconcile net loss to net cash
  used in operating activities:
  Depreciation and amortization                               418,062        406,738
  Provision for doubtful accounts receivable                   22,045
  Settlement of joint marketing agreement                     125,000
Changes in operating assets and liabilities:
  (Increase) decrease in accounts receivable                 (447,120)       (97,599)
  Increase in inventories                                    (466,091)      (484,900)
  (Increase) decrease in prepaid expenses and
    other current assets                                     (514,309)        83,658
  Increase (decrease) in accounts payable                     834,497       (225,182)
  (Increase) decrease in accrued liabilities                  420,667       (141,063)
                                                         ------------   ------------

           Net cash used in operating activities           (1,277,497)    (3,181,419)
                                                         ------------   ------------


CASH FLOWS FROM INVESTING ACTIVITIES:
  Purchase of property and equipment                          (16,598)      (130,161)
  Patent expenditures                                         (90,431)       (98,867)
                                                         ------------   ------------ 
       Net cash used in investing operating activities       (107,029)      (229,028)
                                                         ------------   ------------ 

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from Credit Facility                             1,000,000
  Proceeds from exercise of Class A Warrants                  300,774
  Proceeds from issuance of notes payable                     169,332
                                                         ------------   ------------
           Net cash provided by financing activities        1,470,106              0
                                                         ------------   ------------

          Net increase (decrease) in cash                      85,580     (3,410,447)

Cash and cash equivalents at beginning of period               35,463      5,888,237
                                                         ------------   ------------

Cash and cash equivalents at end of period              $     121,043  $   2,477,790
                                                         ------------   ------------
                                                         ------------   ------------
SUPPLEMENTAL DISCLOSURES:
  Noncash investing activities
     Settlement of joint marketing agreement:           $     206,740

</TABLE>


                See condensed notes to unaudited financial statements.


                                      -12-
<PAGE>

                             PREMIER LASER SYSTEMS, INC.
                  CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS


NOTE 1:  GENERAL

In the opinion of the Company's management, the accompanying unaudited
statements include all adjustments (which include only normal recurring
adjustments) necessary for a fair presentation of the financial position of the
Company at September 30, 1996 and the results of operations and cash flows for
the six months ended September 30, 1996 and 1995.  Although the Company believes
that the disclosures in these financial statements are adequate to make the
information presented not misleading, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to the rules and regulations of the Securities and Exchange Commission.
Results of operations for interim periods are not necessarily indicative of
results of operations to be expected for the full year.

The financial information in this quarterly report should be read in conjunction
with the audited March 31, 1996 financial statements and notes thereto included
in the Company's annual report filed on Form 10-KSB.

The Company has suffered recurring losses from operations and may continue to
incur losses for the foreseeable future due to the significant costs anticipated
to be incurred in connection with manufacturing, marketing and distributing its
laser products.  In addition, the Company intends to conduct continuing research
and development activities, including regulatory submittals and clinical trials
to develop additional applications for its laser technology.  The Company is
subject to all of the risks inherent in new business enterprises.  It is
anticipated that these difficulties will be compounded by the highly competitive
environment in which the Company operates.

NOTE 2:  AS ADJUSTED BALANCE SHEET INFORMATION (UNAUDITED)

The as adjusted information presented in the accompanying unaudited balance
sheet as of September 30, 1996 reflects (i) the receipt of net proceeds of
$10,676,750 from the Company's secondary offering and the exercise of the
underwriter's over-allotment option, both of which closed subsequent to
September 30, 1996; (ii) the repayment of a $481,195 note payable to Pfizer
HPG;  (iii) the payment of $1,100,000 of accounts payable; and (iv) the
payment of $18,138 of accrued liabilities.

NOTE 3:  SHORT-TERM INVESTMENTS, STRATEGIC ALLIANCE


In December 1995, the Company entered into a strategic marketing alliance with
Mattan Corporation (Mattan), a Canadian corporation whose stock is publicly
traded on the Alberta Stock Exchange.  The purchasing agreement (the Agreement)
stipulates that the Company will supply all laser equipment and associated
disposables for all laser surgery centers to be designed and opened by Mattan in
Canada and the United States.  It is anticipated that these surgery centers will
be operated under the name of Medical Laser Institute of America.  In connection
with this alliance, the Company also entered into a share exchange agreement
pursuant to which


                                      -13-
<PAGE>

the Company issued 200,000 shares of the Company's Class A Common Stock  to
certain parties

affiliated with Mattan, who purchased 1,150,000 shares of Mattan's common stock,
representing approximately 12% of Mattan's common stock, for approximately
$881,010 on the Company's behalf.  Prior to March 31, 1996, the Mattan
affiliates sold the 200,000 shares of the Company's Class A Common Stock and
released the shares of the Mattan common stock to the Company.  The Company
accounts for this investment as an available-for-sale security pursuant to SFAS
115.  At September 30, 1996, the fair value of this investment totaled
approximately $3,037,508 and the related unrealized holding gain totaled
$2,156,508.


NOTE 4:  INVENTORIES


Inventories are summarized as follows:

                                  March 31, 1996      September 30, 1996

    Raw Materials                 $      938,560       $      1,122,659
    Work-in-progress                     276,998                135,782
    Finished goods                       969,797              1,393,005
                                         -------              ---------

                                  $    2,185,355       $      2,651,446
                                  --------------       ----------------

NOTE 5:   LITIGATION


The Company has previously entered into an agreement with Infrared Fiber
Systems, Inc. (IFS), a supplier of certain fiber optics that expires in the
fiscal year ending March 21, 2002 and requires the supplier to sell exclusively
to the Company, fiber optics for medical and dental applications as long as the
Company purchases minimum amounts.

In March 1994, the Company initiated litigation against IFS.  The Company's
complaint alleges that IFS and two of its officers misrepresented IFS' ability
to supply optical fibers, and that IFS breached its supply agreement and certain
warranties.  In April 1994, IFS filed a cross-complaint alleging breach of
contract and intentional interference with prospective economic advantage,
seeking declaratory relief that the contract has been terminated and that IFS is
free to market its fibers to others.  In July 1994, Coherent, Inc., a major
shareholder of IFS and a manufacturer of medical lasers which employ IFS optical
fibers, joined the lawsuit for the express purpose of defending their rights to
the IFS optical fibers.  In May 1995, the Company instituted litigation
concerning this dispute in the Orange County, California Superior Court against
Coherent, Westinghouse Electric Corporation ("Westinghouse") and an individual
employee of Westinghouse who was an officer of IFS from 1986 to 1993, when the
events involved in the federal action against IFS took place and while
Westinghouse owned a substantial minority interest in IFS.  The complaint
charges that Coherent conspired with IFS in the wrongful


                                      -14-
<PAGE>

conduct which is the subject of the federal lawsuit and interfered with the
Company's contracts and relations with IFS and with prospective contracts and
advantageous economic relations with third parties.  The complaint asserts that
Westinghouse is liable for its employee's wrongful acts as an IFS executive
while acting within the scope of his employment at Westinghouse.  The lawsuit
seeks injunctive relief and compensatory damages.  In October 1995, the federal
action was stayed by order of the court in favor of the California state court
action, in which the pleadings have been amended to include all claims asserted
by the Company in the federal action.  In July 1996, the court in the California
state court action granted demurrers by Westinghouse and the employee of
Westinghouse to all causes of action against them, as well as all but one of the
Company's claims against Coherent.  As a result, the claims that are the subject
of the granted demurrers have been dismissed, subject to the Company's right to
appeal.  The Company has decided that it will file an appeal of these decisions.
No trial date has been set.  The Company believes that the likely liability of
the Company, if any, arising from this litigation would not have a materially
adverse impact upon the Company.

The Company is involved in various disputes and other lawsuits from time to time
arising from its normal operations.  The litigation process is inherently
uncertain and it is possible that the resolution of the IFS litigation, disputes
and other lawsuits may adversely affect the Company.  It is the opinion of
management, that the outcome of such matters will not have a material adverse
impact on the Company's financial position, results of operations or cash flows.


                                      -15-
<PAGE>

                                    EXHIBIT INDEX

10.1     Letter agreement dated August 14, 1996 between the Registrant and
         LaserMed (incorporated herein by this reference to Exhibit 10.41 to
         the Registrant's Registration Statement on Form SB-2, File No.
         333-04219).

10.2     Agreement dated August 12, 1996 between the Registrant and Circuit
         Tree Medical, Inc. (incorporated herein by this reference to Exhibit
         10.42 to the Registrant's Registration Statement on Form SB-2, File
         No. 333-04219).

10.3     Letter agreement dated August 24, 1996 between the Registrant, Tower
         Financial Group and International Biolaser Corporation (incorporated
         herein by this reference to Exhibit 10.43 to the Registrant's
         Registration Statement on Form SB-2, File No. 333-04219).

10.4     Amendment to Loan Agreement dated October 9, 1996 between the
         Registrant and Silicon Valley Bank (incorporated herein by this
         reference to Exhibit 10.44 to the Registrant's Registration Statement
         on Form SB-2, File No. 333-04219).


                                      -16-